BR112023018735A2 - Construtos de citocinas ativáveis mascarados e composições e métodos relacionados - Google Patents

Construtos de citocinas ativáveis mascarados e composições e métodos relacionados

Info

Publication number
BR112023018735A2
BR112023018735A2 BR112023018735A BR112023018735A BR112023018735A2 BR 112023018735 A2 BR112023018735 A2 BR 112023018735A2 BR 112023018735 A BR112023018735 A BR 112023018735A BR 112023018735 A BR112023018735 A BR 112023018735A BR 112023018735 A2 BR112023018735 A2 BR 112023018735A2
Authority
BR
Brazil
Prior art keywords
methods
masked
cytokine
related compositions
activable
Prior art date
Application number
BR112023018735A
Other languages
English (en)
Inventor
Yevgenyevich Berezhnoy Alexey
L Daniel Dylan
Le Scolan Erwan
Haizar Assi Hikmat
Hsin Wang
M Paidhungat Madan
Na Cai
G Lapuyade Nicole
Sayantan Mitra
A Bogdanoff Walter
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of BR112023018735A2 publication Critical patent/BR112023018735A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

construtos de citocinas ativáveis mascarados e composições e métodos relacionados. são fornecidos neste documento construtos de citocinas ativáveis que incluem: (a) um primeiro construto de monômero compreendendo uma primeira máscara de peptídeo (pm1), uma terceira fração clivável (cm3), uma primeira proteína de citocina madura (cp1), uma primeira fração clivável (cm1), e um primeiro domínio de dimerização (dd1), em que a cm1 está posicionada entre a cp1 e o dd1, e a cm3 está posicionada entre a pm1 e a cp1; e (b) um segundo construto de monômero compreendendo uma segunda proteína de citocina madura (cp2), uma segunda fração clivável (cm2) e um segundo domínio de dimerização (dd2), onde a cm2 está posicionada entre a cp2 e o dd2, onde o dd1 e dd2 se ligam; e onde o acc é caracterizado por uma redução em pelo menos uma atividade da cp1 e/ou da cp2 em comparação com um nível de controle de pelo menos uma atividade da cp1 e/ou da cp2.
BR112023018735A 2021-03-16 2022-03-16 Construtos de citocinas ativáveis mascarados e composições e métodos relacionados BR112023018735A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161913P 2021-03-16 2021-03-16
US202163164827P 2021-03-23 2021-03-23
US202163254748P 2021-10-12 2021-10-12
US202163276893P 2021-11-08 2021-11-08
PCT/US2022/020492 WO2022197764A2 (en) 2021-03-16 2022-03-16 Masked activatable cytokine constructs and related compositions and methods

Publications (1)

Publication Number Publication Date
BR112023018735A2 true BR112023018735A2 (pt) 2023-11-28

Family

ID=81389111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018735A BR112023018735A2 (pt) 2021-03-16 2022-03-16 Construtos de citocinas ativáveis mascarados e composições e métodos relacionados

Country Status (11)

Country Link
US (2) US11667687B2 (pt)
EP (1) EP4308594A2 (pt)
JP (1) JP2024511387A (pt)
KR (1) KR20230157448A (pt)
AU (1) AU2022237504A1 (pt)
BR (1) BR112023018735A2 (pt)
CA (1) CA3211924A1 (pt)
IL (1) IL305716A (pt)
MX (1) MX2023010840A (pt)
TW (1) TW202304958A (pt)
WO (1) WO2022197764A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3233707A1 (en) * 2021-10-08 2023-04-13 Alexey Yevgenyevich Berezhnoy Activatable cytokine constructs and combination methods

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
PT1294401E (pt) 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
WO2002030460A2 (en) 2000-10-09 2002-04-18 Isis Innovation Ltd. Therapeutic antibodies
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EP1899368A2 (en) 2005-05-26 2008-03-19 Schering Corporation Interferon-igg fusion
EP1993608A1 (en) 2006-03-10 2008-11-26 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2009079837A1 (fr) 2007-12-18 2009-07-02 Hangzhou Jiuyuan Gene Engineering Co., Ltd. Formulation pharmaceutique contenant une protéine de fusion sérum albumine humaine recombinante-interféron alpha
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
EP2398494A4 (en) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteins and their methods of use
WO2011123683A2 (en) 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
CN103237808B (zh) 2010-12-03 2016-02-24 阿达梅德公司 抗癌融合蛋白
CN103501805B (zh) 2011-01-18 2018-09-14 比奥尼斯有限责任公司 调节γ-C-细胞因子活性的组合物及方法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
EP3049111A2 (en) 2013-09-25 2016-08-03 Cytomx Therapeutics Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
RU2016135239A (ru) 2014-01-31 2018-03-12 Сайтомкс Терапьютикс, Инк. Субстраты матриптазы и u-активатора плазминогена и другие расщепляемые остатки и способы их применения
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
EP3611188B1 (en) 2014-11-06 2022-05-04 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding and methods of use
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
US20190216898A1 (en) 2016-05-06 2019-07-18 Wang Mulin Interleukin Combination and Use Thereof
AU2017342560B2 (en) 2016-10-14 2022-03-17 Xencor, Inc. IL15/IL15Ralpha heterodimeric Fc-fusion proteins
KR20200015742A (ko) 2017-06-20 2020-02-12 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 인터페론 전구약물
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US20230158141A1 (en) 2017-11-08 2023-05-25 Yafei Shanghai Biolog Medicine Science & Technolog Co., Ltd Conjugates of Biomolecule and Use Thereof
WO2019092181A1 (en) 2017-11-10 2019-05-16 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies
US11866466B2 (en) 2017-12-19 2024-01-09 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
WO2020113403A1 (en) 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
US20210260163A1 (en) 2018-03-09 2021-08-26 AskGene Pharma, Inc. Novel cytokine prodrugs
KR20210021467A (ko) 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
SG11202011309SA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of use thereof
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
WO2019246392A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
EP4321530A3 (en) 2018-09-27 2024-05-22 Xilio Development, Inc. Masked cytokine polypeptides
AU2019350466A1 (en) 2018-09-28 2021-04-29 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
TW202033547A (zh) 2018-10-23 2020-09-16 美商蜻蜓醫療公司 異二聚體fc融合蛋白
KR20210102318A (ko) 2018-12-06 2021-08-19 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이스-절단성 기질 및 세린 또는 시스테인 프로테이스-절단성 기질 그리고 이들의 사용 방법
JP2022513888A (ja) 2018-12-14 2022-02-09 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－１５組成物およびその使用方法
US11136353B2 (en) 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
AU2020275877A1 (en) 2019-05-14 2021-12-23 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
KR20220012256A (ko) 2019-05-24 2022-02-03 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
CN114127277A (zh) 2019-06-05 2022-03-01 中外制药株式会社 蛋白酶底物和包含蛋白酶切割序列的多肽
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
WO2021011353A1 (en) 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
WO2021016599A1 (en) 2019-07-25 2021-01-28 Trutino Biosciences Inc Il-2 cytokine prodrugs comprising a cleavable linker
CN114466657A (zh) 2019-07-25 2022-05-10 芝加哥大学 包括蛋白酶激活治疗剂的组合物和方法
JP2022544771A (ja) 2019-08-12 2022-10-21 アスクジーン・ファーマ・インコーポレイテッド 優先的にｉｌ－２ｒアルファに結合するｉｌ－２融合タンパク質
US20220289822A1 (en) 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2020353235A1 (en) 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
US20220402988A1 (en) 2019-12-05 2022-12-22 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
KR20220115611A (ko) 2019-12-13 2022-08-17 큐진 인크. 사이토카인-기반 생체활성 약물 및 이의 사용 방법
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
US20240043489A1 (en) 2020-01-15 2024-02-08 Trutino Biosciences Inc. Cytokine Prodrugs Comprising a Cleavable Linker
US20230122079A1 (en) 2020-03-23 2023-04-20 Zymeworks Inc. Masked il12 fusion proteins and methods of use thereof
WO2021202354A1 (en) 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
AU2021245922A1 (en) 2020-04-01 2022-10-13 Xilio Development, Inc. Masked IL-2 cytokines and their cleavage products
BR112022019708A2 (pt) 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
TW202204385A (zh) 2020-04-01 2022-02-01 美商艾希利歐發展股份有限公司 經遮蔽之il-15細胞激素及其裂解產物
BR112022020440A2 (pt) 2020-04-10 2022-12-27 Cytomx Therapeutics Inc Construtos de citocinas ativáveis e composições e métodos relacionados
WO2021222762A2 (en) 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Activatable il2 composition and methods of use
CA3178657A1 (en) 2020-05-19 2021-11-25 William Winston Activatable il-12 polypeptides and methods of use thereof

Also Published As

Publication number Publication date
US20240124546A1 (en) 2024-04-18
AU2022237504A1 (en) 2023-10-05
JP2024511387A (ja) 2024-03-13
CA3211924A1 (en) 2022-09-22
IL305716A (en) 2023-11-01
WO2022197764A2 (en) 2022-09-22
US20220306717A1 (en) 2022-09-29
EP4308594A2 (en) 2024-01-24
TW202304958A (zh) 2023-02-01
MX2023010840A (es) 2023-10-26
WO2022197764A3 (en) 2022-11-03
US11667687B2 (en) 2023-06-06
KR20230157448A (ko) 2023-11-16

Similar Documents

Publication Publication Date Title
BR112022020440A2 (pt) Construtos de citocinas ativáveis e composições e métodos relacionados
BR112023018735A2 (pt) Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
Overall et al. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-β
Weems et al. Prostaglandins and reproduction in female farm animals
Pufe et al. The angiogenic peptide vascular endothelial growth factor is expressed in foetal and ruptured tendons
Lapière et al. Procollagen peptidase: an enzyme excising the coordination peptides of procollagen
BR9909677A (pt) Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas
ES2031826T3 (es) Procedimiento para producir nuevos peptidos activadores del plasminogeno.
ECSP22061711A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
ATE408583T1 (de) Medizinisch genaues pumpsystem
Quintana et al. In-vivo activity of IFN-λ and IFN-α against bovine-viral-diarrhea virus in a mouse model
Samuel Mechanism of interferon action. Kinetics of interferon action in mouse L929 cells: phosphorylation of protein synthesis initiation factor eIF-2 and ribosome-associated protein P1
NO20000872L (no) FremgangsmÕte til fremstilling av vinylestere fra butenoligomerer
AR125090A1 (es) Construcciones de citoquinas activables enmascaradas y composiciones y métodos relacionados
Woessner Jr Pepstatin inhibits the digestion of hemoglobin and protein-polysaccharide complex by cathepsin D
BR112023003517A2 (pt) Moduladores da proteína proto-oncogênica da família myc
Galewska et al. Matrix metalloproteinases, MMP-7 and MMP-26, in plasma and serum of control and preeclamptic umbilical cord blood
WO2023060156A3 (en) Activatable cytokine constructs and related compositions and methods
Lin et al. Tomoregulin ectodomain shedding by proinflammatory cytokines
BR112023016442A2 (pt) Composições de soluções aquosas para aumentar a estabilidade de proteínas diméricas modificadas
BR0014634A (pt) Proteìnas dp de trigo e uso das mesmas
ES2123669T3 (es) Derivados del plasminogeno que se activan con trombina.
DE602005010734D1 (de) Indolderivate als progesteron-rezeptormodulatoren
Sobolewski et al. The activity of collagen-degrading enzymes of Wharton’s jelly in EPH gestosis (pre-eclampsia)
CN210579323U (zh) 氙灯发光控制电路